KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gross Profit (2019 - 2025)

Historic Gross Profit for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q3 2025 value amounting to $1.1 billion.

  • Alnylam Pharmaceuticals' Gross Profit rose 15106.16% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 1730.84%. This contributed to the annual value of $1.9 billion for FY2024, which is 2446.38% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Gross Profit stood at $1.1 billion for Q3 2025, which was up 15106.16% from $631.7 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Gross Profit's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of -$40.2 million in Q1 2025.
  • Moreover, its 5-year median value for Gross Profit was $277.9 million (2023), whereas its average is $356.4 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Gross Profit surged by 19458.29% in 2023 and then plummeted by 10913.83% in 2025.
  • Alnylam Pharmaceuticals' Gross Profit (Quarter) stood at $224.9 million in 2021, then grew by 28.44% to $288.9 million in 2022, then increased by 27.31% to $367.7 million in 2023, then skyrocketed by 33.39% to $490.5 million in 2024, then soared by 114.43% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $631.7 million for Q2 2025, and -$40.2 million during Q1 2025.